BioNeutral Announces 100% Total Kill of Swine Flu (H1N1) on Virtual Contact of This Pandemic Causing Virus in an Independent ...
August 18 2009 - 8:30AM
Business Wire
BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty
chemical technology based Life Science Company, announced today
that independent lab test results conducted at Microbiotest Inc. of
Sterling, Virginia demonstrated that Ygiene™ Hospital Grade
Antimicrobial totally eradicated the H1N1 Swine Flu virus in 20
seconds (Virtual Contact). This independent testing shows that
Ygiene™ Hospital Grade Antimicrobial is extremely effective against
the Swine Flu. BioNeutral’s Ygiene™ Hospital Grade Antimicrobial is
also one of a few antimicrobials actually tested against the
specific H1N1 Swine Flu Virus.
On June 11th the
World Health Organization (WHO) declared that the original outbreak
of Swine Flu (H1N1)
had progressed unabated to a global
pandemic Level 6, meaning that isolation and control of human to
human infection within a single nation or global region was not
possible. Current concerns with the Swine Flu are that it
may return to North America this fall in an even more resilient
viral form. While many current commercial antimicrobials are
believed to be effective against the Swine Flu Virus, only a
handful have actually been tested against the H1N1 (Swine Flu)
Virus. If the Swine Flu Virus reappears in a more resilient mutated
viral form, the likelihood increases that the untested
antimicrobials currently on the market may not be effective against
this virus. In addition, many of today’s commercial antimicrobials
require an extremely long contact time of 10 minutes to be
effective against the flu virus. In contrast, the Ygiene™ Hospital
Grade Antimicrobial, developed by BioNeutral, requires only 20
seconds of contact time, making cleaning and elimination of the
virus more realistic in today’s world where speed is of the
essence. The speed of BioNeutral’s Ygiene™ Hospital Grade
Antimicrobial will meet these time to kill demands.
Recently, former Secretary of Homeland Security, Michael
Chertoff and Dr. J. Bennet Waters wrote an article about the
problems and issues associated with a pandemic. In the article
(chertoffgroup.com) they explain that using old conventional
thinking and “treating a pandemic as
a health problem is not just bad policy, it is a dangerous
approach." Associated with a
pandemic are a myriad of diplomatic, economic and national security
consequences along with complex operational issues at all levels,
in all sectors. Plans to deal with a pandemic must include
prevention, detection, response and recovery. BioNeutral believes
that its Ygiene™ Hospital Grade Antimicrobial will be an integral
part of a comprehensive plan that deals with a pandemic such as the
Swine Flu.
BioNeutral Group CEO, Stephen J. Browand, stated "Ygiene is an
inexpensive, Green to the environment, non corrosive, non-staining,
mild to the touch chemical formulation, which out performs all
other antimicrobials and will become the solution of choice once
approved by the EPA for commercialization in the United
States. The company is in discussions to distribute and
license its groundbreaking technology which includes a family of
formulations that are all sporicidal.”
Chief Scientist at BioNeutral Group, Dr. Andy Kielbania stated
“These independent lab results continue to verify the exceptional
efficacy and speed to kill of our Ygiene™ Hospital Grade
Antimicrobial. In addition, our strategy of raising the bar on
antimicrobial performance includes actually testing against the
microorganisms where we intend to make our EPA claims. We prefer
not to make claims by extrapolating scientific data since this
approach may lead to invalid conclusions.” He continued, “We also
believe for an antimicrobial to be effective it must eradicate
quickly like the 20 seconds demonstrated by our Ygiene™ Hospital
Grade. Based upon all the independent testing results obtained to
date on our Ygiene™ antimicrobial, we believe it will also be
extremely effective and have a beneficial toxicity profile and a
significant cost performance advantage when used in a diluted form
against the H1N1 virus. We are currently pursuing this approach.
The 10 minute required contact time claimed by many of today’s
commercial disinfectants is much too long since those individuals
responsible for cleaning areas may not rigorously follow these
extended time requirements. Developing our world class
antimicrobials with rapid kill times is an important part of our
strategy of raising the bar on today’s antimicrobial
performance.”
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in
Newark, New Jersey, BioNeutral Group, Inc., is a chemical
technology-based Life Science company that intends to commercialize
a combinational chemistry-based technology which can neutralize
harmful environmental contaminants, toxins and dangerous
micro-organisms including bacteria, viruses, mold, fungi and
spores. The formulations, including Ygiene™ and Ogiene™, which are
eco-friendly and include natural and common ingredients which are
found in baby products and in every day foods. The Company has
combined these widely-used compounds in highly specialized ways to
create products that dramatically enhance disinfecting and cleaning
results; products include BioNeutralizers and ChemoNeutralizers.
BioNeutral’s proprietary platform technology has been proven
effective in surface, water and airborne applications.
More information about the Company may be found at
www.bioneutralgroup.com
About Microbiotest Inc.
Microbiotest Inc. located in Sterling Virginia is a world
recognized laboratory with over 20 years of experience in testing a
broad spectrum of microbiological materials. Microbiotest
effectively collaborates and has an excellent track record with its
clients that are developing new products to meet various Agency
regulatory requirements using recognized protocols both in North
America and abroad. In addition Microbiotest has the ability to
design unique tests for special situations.
Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its
competitors. The results are published to let shareholders know how
the Company's technology compares with known formulations in the
market place. Any product claim for antimicrobial activity requires
approval from the EPA or FDA, depending upon where and how the
formulations are used. The EPA and FDA have not reviewed or
confirmed the Company's data and findings. BioNeutral's
antimicrobial formulations will be marketed under the brand name
Ygiene™ and are not yet available for sale in the United
States.